KROS - Keros Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$102.60
DETAILS
HIGH:
$107.00
LOW:
$96.00
MEDIAN:
$105.00
CONSENSUS:
$102.60
UPSIDE:
811.19%
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||
| Revenue | 244.1 | 3.5 | 0.2 | 0 | 20.1 | 0 | 10 | 10 |
| Cost of Revenue | 1.5 | 0 | 0 | 0 | 0 | 0.6 | 17.3 | 10.1 |
| Gross Profit | 242.6 | 3.5 | 0.2 | 0 | 20.1 | (0.6) | (7.3) | (0.1) |
| Operating Expenses | ||||||||
| R&D Expenses | 129.6 | 173.6 | 135.3 | 87.3 | 55.1 | 33.9 | 17.4 | 10.1 |
| SG&A Expenses | 46.8 | 40.8 | 34.8 | 27.5 | 21.3 | 12.2 | 3.2 | 1.6 |
| Other Expenses | (4.6) | 0 | 0 | 0 | 0 | 0 | (0.6) | 0.2 |
| Operating Expenses | 171.9 | 214.4 | 170.1 | 114.8 | 76.5 | 46.1 | 20.0 | 11.3 |
| Operating Income | ||||||||
| Operating Income | 70.6 | (210.8) | (169.9) | (114.8) | (56.4) | (46.7) | (10.6) | (1.7) |
| Interest Expense | 0 | 0 | 0 | 0.0 | 0.0 | 0.0 | 0.0 | 0 |
| Interest Income | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Profitability | ||||||||
| EBITDA | 93.4 | (185.8) | (152.2) | (104.0) | (56.4) | (44.9) | (11.9) | (0.8) |
| EBIT | 91.9 | (187.1) | (153.0) | (104.7) | (56.7) | (45.5) | (12.3) | (1.3) |
| Income Before Tax | 91.9 | (187.1) | (153.0) | (104.7) | (56.7) | (45.5) | (12.3) | (1.1) |
| Income Tax Expense | 4.9 | 0.3 | 0 | 0 | 2.0 | (0.2) | 0 | 0.3 |
| Net Income | 87.0 | (187.4) | (153.0) | (104.7) | (58.7) | (45.4) | (12.3) | (1.3) |
| Per Share Data | ||||||||
| EPS (Basic) | 2.34 | -5.00 | -5.20 | -4.15 | -2.52 | -2.93 | -1.39 | -0.15 |
| EPS (Diluted) | 2.30 | -5.00 | -5.20 | -4.15 | -2.52 | -2.93 | -1.39 | -0.15 |
| Shares Outstanding | 37.2 | 37.4 | 29.4 | 25.2 | 23.3 | 15.5 | 8.9 | 8.9 |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Current Assets | ||||||||
| Cash & Cash Equivalents | 287.4 | 559.9 | 331.1 | 279.0 | 230.0 | 265.9 | 7.0 | 23.3 |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 6.4 | 4.5 | 1.1 | 0.8 | 18.2 | 0.2 | 0.9 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 2.4 | 1.5 | 1.0 | 0.3 | 0.2 | 0.2 | 0.8 | 0.1 |
| Total Current Assets | 315.4 | 588.9 | 347.3 | 285.8 | 251.4 | 267.7 | 8.9 | 25.5 |
| Non-Current Assets | ||||||||
| Property, Plant & Equipment | 21.1 | 23.5 | 19.5 | 17.6 | 2.4 | 1.6 | 1.9 | 1.4 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 1.4 | 1.4 | 1.2 | 0 | 0 | 0 | 0 | 0.5 |
| Other Non-Current Assets | 0 | 2.1 | 2.1 | 3.4 | 1.4 | 0.1 | 0.1 | 0 |
| Total Non-Current Assets | 22.6 | 27.0 | 22.7 | 21.0 | 3.8 | 1.7 | 2.0 | 1.9 |
| Total Assets | 338.0 | 615.9 | 370.0 | 306.8 | 255.3 | 269.4 | 11.0 | 27.4 |
| Current Liabilities | ||||||||
| Account Payables | 2.0 | 4.6 | 5.5 | 3.3 | 3.6 | 2.1 | 2.1 | 0.5 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 |
| Other Current Liabilities | 6.1 | 10.5 | 10.4 | 5.6 | 2.6 | 1.7 | 1.0 | 0.5 |
| Total Current Liabilities | 20.4 | 27.4 | 24.4 | 16.5 | 11.8 | 7.2 | 4.5 | 11.5 |
| Non-Current Liabilities | ||||||||
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0.1 | 5.1 | 2.6 |
| Total Non-Current Liabilities | 14.5 | 16.9 | 13.4 | 12.8 | 0.2 | 0.5 | 6.0 | 3.2 |
| Total Liabilities | 34.9 | 44.3 | 37.8 | 29.4 | 12.1 | 7.7 | 10.5 | 14.7 |
| Stockholders' Equity | ||||||||
| Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Retained Earnings | (481.8) | (568.8) | (381.4) | (228.4) | (123.8) | (65.0) | (19.6) | (7.3) |
| Accumulated Other Comprehensive Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (0.2) |
| Total Stockholders' Equity | 303.1 | 571.6 | 332.2 | 277.4 | 243.2 | 261.7 | 0.5 | 12.8 |
| Total Liabilities & Equity | 338.0 | 615.9 | 370.0 | 306.8 | 255.3 | 269.4 | 11.0 | 27.4 |
| Debt Metrics | ||||||||
| Total Debt | 16.9 | 18.9 | 14.4 | 13.3 | 1.1 | 0.9 | 1.3 | 0.8 |
| Net Debt | (270.5) | (541.1) | (316.7) | (265.8) | (228.9) | (265.0) | (5.7) | (22.5) |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | 87.0 | (187.4) | (153.0) | (104.7) | (58.7) | (45.4) | (12.3) | (1.3) |
| Depreciation & Amortization | 1.5 | 1.2 | 0.8 | 0.7 | 0.4 | 0.3 | 0.4 | 0.2 |
| Stock-Based Compensation | 28.7 | 34.9 | 28.8 | 18.7 | 11.7 | 4.1 | 0 | 0.1 |
| Change in Working Capital | (12.1) | (11.4) | (2.6) | 14.3 | (16.1) | 2.3 | (6.7) | 7.9 |
| Other Non-Cash Items | 2.4 | 1.8 | 1.6 | 1.0 | 0.5 | 1.8 | 2.6 | 0.2 |
| Operating Cash Flow | 107.5 | (160.9) | (124.5) | (70.1) | (62.1) | (36.9) | (16.0) | 7.0 |
| Investing Activities | ||||||||
| Capital Expenditure | (1.6) | (1.9) | (2.5) | (1.2) | (1.0) | (0.3) | (0.3) | (0.2) |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sales/Maturities of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (1.6) | (1.9) | (2.5) | (1.2) | (1.0) | (0.3) | (0.3) | (0.2) |
| Financing Activities | ||||||||
| Net Debt Issuance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock Repurchased | (375) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 11.7 | 3.1 | 0.7 | 0.4 | (3.2) | 0 | (0.0) |
| Financing Cash Flow | (378.5) | 391.8 | 179.0 | 120.3 | 28.6 | 296.0 | 0.0 | 11.5 |
| Cash Position | ||||||||
| Net Change in Cash | (272.5) | 229.0 | 52.0 | 49.0 | (34.6) | 258.9 | (16.2) | 18.3 |
| Cash at Beginning | 561.4 | 332.4 | 280.4 | 231.4 | 266.0 | 7.1 | 23.3 | 5.1 |
| Cash at End | 288.9 | 561.4 | 332.4 | 280.4 | 231.4 | 266.0 | 7.0 | 23.4 |
| Free Cash Flow | 106.0 | (162.8) | (127.0) | (71.3) | (63.2) | (37.2) | (16.3) | 6.8 |
| Key Metrics | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 244.1 | 3.5 | 0.2 | 0 | 20.1 | 0 | 10 | 10 |
| Gross Profit | 242.6 | 3.5 | 0.2 | 0 | 20.1 | (0.6) | (7.3) | (0.1) |
| Operating Income | 70.6 | (210.8) | (169.9) | (114.8) | (56.4) | (46.7) | (10.6) | (1.7) |
| Net Income | 87.0 | (187.4) | (153.0) | (104.7) | (58.7) | (45.4) | (12.3) | (1.3) |
| EPS (Diluted) | 2.30 | -5.00 | -5.20 | -4.15 | -2.52 | -2.93 | -1.39 | -0.15 |
| Balance Sheet | ||||||||
| Cash & Equivalents | 287.4 | 559.9 | 331.1 | 279.0 | 230.0 | 265.9 | 7.0 | 23.3 |
| Total Assets | 338.0 | 615.9 | 370.0 | 306.8 | 255.3 | 269.4 | 11.0 | 27.4 |
| Total Debt | 16.9 | 18.9 | 14.4 | 13.3 | 1.1 | 0.9 | 1.3 | 0.8 |
| Stockholders' Equity | 303.1 | 571.6 | 332.2 | 277.4 | 243.2 | 261.7 | 0.5 | 12.8 |
| Cash Flow | ||||||||
| Operating Cash Flow | 107.5 | (160.9) | (124.5) | (70.1) | (62.1) | (36.9) | (16.0) | 7.0 |
| Capital Expenditure | (1.6) | (1.9) | (2.5) | (1.2) | (1.0) | (0.3) | (0.3) | (0.2) |
| Free Cash Flow | 106.0 | (162.8) | (127.0) | (71.3) | (63.2) | (37.2) | (16.3) | 6.8 |